Key result
Abciximab is a dependable glycoprotein IIb/IIIa inhibitor recommended for patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Why the study?
Does abciximab prevent thrombus formation in patients with acute coronary syndromes undergoing percutaneous coronary intervention?
Does abciximab prevent thrombus formation in patients with acute coronary syndromes undergoing percutaneous coronary intervention?
Abciximab remains a highly recommended GP IIb/IIIa inhibitor for STEMI patients undergoing primary PCI, with unique benefits including no renal dose adjustment and reversibility via platelet transfusion.
Supports abciximab consideration in STEMI primary PCI for dosing advantages; literature review leaves open need for contemporary RCTs.
The glycoprotein (GP) IIb/IIIa receptor serves as the final common pathway of platelet-thrombus formation. Thus, the GP IIb/IIIa receptor has been identified as a target for the prevention of thrombus formation during acute coronary syndromes and/or percutaneous coronary intervention. While there are several intravenous GP IIb/IIIa inhibitors available, abciximab has proven to be a dependable agent with unique properties. Based on American College of Cardiology, American Heart Association and Society for Angiography and Interventions guidelines, compared with the other available intravenous GP IIb/IIIa inhibitors, abciximab receives the highest recommendation for use in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Abciximab is also unique in that there is no need for renal dosing and its effects are mostly reversible with platelet transfusions.
No takes yet. Share an insight, caveat, or question.
Mazzaferri et al. (2008) conducted a review in Acute coronary syndromes and/or percutaneous coronary intervention. Abciximab vs. Other intravenous GP IIb/IIIa inhibitors was evaluated. Abciximab is a dependable glycoprotein IIb/IIIa inhibitor recommended for patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: